References
1. Brachman
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1522900/
2. The Department of Defense Anthrax Vaccine Immunization Program: Unproven Force Protection Fourth Report by the Committee on Government Reform
https://www.govinfo.gov/content/pkg/CRPT-106hrpt556/html/CRPT-106hrpt556.htm
3. Research Advisory Committee on Gulf War Veterans' Illnesses Gulf War Illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations Washington, D.C.: U.S. Government Printing Office, November 2008
https://www.va.gov/RAC-GWVI/docs/Committee_Documents/GWIandHealthofGWVeterans_RAC-GWVIReport_2008.pdf
4. Clarifying Guidance for the Smallpox and Anthrax Vaccination Programs
https://www.centcom.mil/AREA-OF-RESPONSIBILITY/
5. VAERS database
https://vaers.hhs.gov/
6. What is a Serious Adverse Event?
https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
7. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Rosenthal S1, Chen R. 1995.
http://www.ncbi.nlm.nih.gov/pubmed/7503351
8. Electronic Support for Public Health-Vaccine Adverse Event Reporting System
https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf
9. Is the US's Vaccine Adverse Event Reporting System broken?
https://www.bmj.com/content/383/bmj.p2582
10. Clinical Policy for the Administration of Anthrax Vaccine Adsorbed July 31st 2009
https://health.mil/Reference-Center/Policies/2009/07/31/Clinical-Policy-for-the-Administration-of-the-Anthrax-Vaccine-Adsorbed
11. U.S. General Accounting Office. Anthrax Vaccine: GAO's Survey of Guard and Reserve Pilots and Aircrew. Washington, D.C. Sep, 2002.
https://www.gao.gov/assets/gao-02-445.pdf
12. The Anthrax Vaccine: Is It Safe? Does It Work? (2002)
https://nap.nationalacademies.org/catalog/10310/the-anthrax-vaccine-is-it-safe-does-it-work
13. Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, and Vaccines
http://iom.nationalacademies.org/Reports/2000/Gulf-War-and-Health-Vol-1-Depleted-Uranium-Sarin-Pyridostigmine-Bromide-and-Vaccines.aspx
14. DoD Faces Challenges in implementing its Anthrax Vaccine Immunisation Program
https://www.gao.gov/products/NSIAD-00-36
15. GAO: Military Health: DOD's Vaccine Healthcare Centers Network 29th June 2007.
http://www.gao.gov/new.items/d07787r.pdf
16. https://www.health.mil/Military-Health-Topics/Health-Readiness/AFHSD/Data-Management-and-Technical-Support/Defense-Medical-Surveillance-System
17. The Defense Medical Surveillance System and the Department of Defense Serum Repository: Glimpses of the Future of Public Health Surveillance Rubertone M 2002
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447349/
18. U.S. Barred From Forcing Troops to Get Anthrax Shots
https://www.washingtonpost.com/archive/politics/2004/10/28/us-barred-from-forcing-troops-to-get-anthrax-shots/563b1195-3fdd-475c-808f-53428137bfc8/
19. US soldiers refuse to fall in line with anthrax vaccination scheme
https://www.nature.com/articles/nm0204-112b
20. Comprehensive systematic surveillance for adverse effects of Anthrax Vaccine Adsorbed, US Armed Forces, 1998–2000Jeffrey L. Lange et al. 2003
https://pubmed.ncbi.nlm.nih.gov/12639483/
21. CDC Anthrax Vaccine Safety and Efficacy Research program
https://www.nap.edu/read/10527/chapter/1
22. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Payne et al. 2007.
http://www.ncbi.nlm.nih.gov/pubmed/16444796
23. Detailed Safety Review of Anthrax Vaccine Adsorbed January 2015 Compiled by the Immunization Healthcare Branch Defense Health Agency, Falls Church, Virginia
https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare/Vaccine-Preventable-Diseases/Anthrax/Anthrax-Resource-Center
24. Risk of disability for US army personnel vaccinated against anthrax, 1998-2005.
Sulsky et al. 2011
https://www.ncbi.nlm.nih.gov/pubmed/21704102
25. Disability among US Army Veterans vaccinated against anthrax. Sulsky et al. 2012.
https://www.ncbi.nlm.nih.gov/pubmed/22874851/
26. Package insert
https://www.fda.gov/media/71954/download
27. https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare/Vaccine-Preventable-Diseases/Anthrax
28. Getting Rich on Uncle Sucker Should the Federal Government Strengthen Efforts to Fight Profiteering? Scott Lilly October 2010
https://www.americanprogress.org/wp-content/uploads/issues/2010/10/pdf/unclesucker_execsumm.pdf
29. Company Led by Top Admiral Buys Michigan Vaccine Lab
https://www.nytimes.com/1998/07/08/us/company-led-by-top-admiral-buys-michigan-vaccine-lab.html
30. Emergent Biosolutions / Bioport Board of Directors: How to Sell to the US Government. Nass, M
http://anthraxvaccine.blogspot.com/2007/06/emergent-biosolutionsbioport-board-of.html
31. Emergent Biosolutions Awarded BARDA Contract for Advanced Development and Delivery of Nuthrax a Next Generation Antrhax Vaccine, Valued at up to $1.6 Billion.
https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-awarded-barda-contract-advanced
32. Data show a difference in incidence of local reactions between lots of Anthrax vaccine: short-term safety experience in humans Pittman P 2001
https://pubmed.ncbi.nlm.nih.gov/11738765/
33. Encl. 18: Microscopy video, pin prick blood from Th1 chronically ill patients.
http://www.autoimmunityresearch.org/lax2006.ram
34. Bacterial persistence and expression of disease. Domingue et al. 1997.
https://www.ncbi.nlm.nih.gov/pubmed/9105757
35. Demystifying pleomorphic forms in persistence and expression of disease: Are they bacteria, and is peptidoglycan the solution? Domingue. 2010
https://www.ncbi.nlm.nih.gov/pubmed/20875345
36. Cell Wall-deficient Bacteria as a Cause of Infections: a Review of the Clinical Significance. Onwuamaegbu et el. 2005.
https://www.ncbi.nlm.nih.gov/pubmed/15651712
37. Microbe-microbe and host-microbe interactions drive microbiome dysbiosis and inflammatory processes. Proal et al. 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28245427
38. New insights into bacterial persistence in reactive arthritis. Astraukiene et al. 2007.
https://www.ncbi.nlm.nih.gov/pubmed/17631749
39. L-form bacteria cohabitants in human blood: significance for health and diseases.
Markova. 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28715646
40. Differential transcriptional response in macrophages infected with cell wall deficient versus normal Mycobacterium Tuberculosis. Fu et al. 2015.
https://www.ncbi.nlm.nih.gov/pubmed/25552926
41. Interaction of alveolar macrophages with Staphylococcus aureus and induction of microbial L-forms during infection in rats. Michailova et al. 2000.
https://www.ncbi.nlm.nih.gov/pubmed/10959728
42. Atypical behaviour and survival of Streptococcus pyogenes L forms during intraperitoneal infection in rats. Michailova et al. 2000.
https://www.ncbi.nlm.nih.gov/pubmed/10767608
43. Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma. Ou et al. 2014.
https://www.ncbi.nlm.nih.gov/pubmed/24589592
44. Cell-wall-deficient bacteria: a major etiological factor for psoriasis? Wang et al. 2009.
https://www.ncbi.nlm.nih.gov/pubmed/20137493
45. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Amar et al. 2011.
https://www.ncbi.nlm.nih.gov/pubmed/2197614
46. How bacterial pathogens colonize their hosts and invade deeper tissues.
Ribet et al. 2015.
https://www.ncbi.nlm.nih.gov/pubmed/25637951
47. New Insights into Bacterial Persistence in Reactive Arthritis Astrauskiene et al. 2007
https://pubmed.ncbi.nlm.nih.gov/17631749/
48. The Dormant Blood Micribiome in Chronic Inflammatory Illnesses Poteieter et el. 2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487407/
49. Filterable forms and L-forms of Mycobacterium bovis BCG: impact for live vaccine features. Markova et a. 2012.
https://www.ncbi.nlm.nih.gov/pubmed/22495116
50. Presence of mycobacterial L-forms in human blood: Challenge of BCG vaccination.
Markova et al. 2015.
https://www.ncbi.nlm.nih.gov/pubmed/25874947
51. Inflammatory disease and the human microbiome. Proal et al. 2014.
https://www.ncbi.nlm.nih.gov/pubmed/24882717
52. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. Proal et al. 2013.
https://www.ncbi.nlm.nih.gov/pubmed/23576059
53. The human microbiome and autoimmunity. Proal et al. 2013.
https://www.ncbi.nlm.nih.gov/pubmed/23370376
54. Immunostimulation in the era of the metagenome. Proal et al. 2011.
https://www.ncbi.nlm.nih.gov/pubmed/21278764
55. Autoimmune disease in the era of the metagenome. Proal et al. 2009.
https://www.ncbi.nlm.nih.gov/pubmed/19393196
56. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Marshall TG et al. 2006.
https://www.ncbi.nlm.nih.gov/pubmed/16403216
57. https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare/Vaccine-Recommendations/Vaccine-Recommendations-by-AOR
58. Children’s Health Defense
https://childrenshealthdefense.org/defender/welcome-to-the-defender/
59. Informed Consent Action Network
https://icandecide.org/
60. Prevalence and patterns of Gulf War Illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Steele L. 2000
https://pubmed.ncbi.nlm.nih.gov/11092441/
61. Health and exposures of United Kingdom Gulf War Veterans, II: the relation of health to exposure. Cherry N, et al. 2001
Part 1 https://oem.bmj.com/content/58/5/291
Part 2 https://oem.bmj.com/content/58/5/299
62. Health of UK servicemen who served in Persian Gulf War. Unwin C, et al. 1999.
https://pubmed.ncbi.nlm.nih.gov/9923871/
63. Role of vaccinations as risk factors for ill health in veterans of the Gulf War: cross sectional study. Hotoph M, et al. 2000.
https://pubmed.ncbi.nlm.nih.gov/10818024/
64. Reanalysis of Gulf War vaccination data does not contradict
findings. Hotoph M. 2000
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1127872/
65. Anthrax vaccination and self-reported symptoms, functional status and medical conditions inthe national health survey of Gulf War era veterans and their families Mahan CM et al. 2004
https://pubmed.ncbi.nlm.nih.gov/15018879/
66. Increased symptom reporting was associated with several exposures, including having more than 10 immunisations, Kelsall et al. 2004
https://pubmed.ncbi.nlm.nih.gov/15550607/
67. CDC children’s vaccines
https://www.cdc.gov/vaccines/vpd/vaccines-age.html
68. 72 Vaccine Doses and No Placebo Trials
https://icandecide.org/72-vaccine-doses-no-placebo-trials/
69. Data and Statistics on Children’s Mental Health
https://www.cdc.gov/childrensmentalhealth/data.html
70. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, Nadeau KC. The public health impact of parent-reported childhood food allergies in the united states. Pediatrics. 2018;142(6):e20181235.
https://pubmed.ncbi.nlm.nih.gov/30455345/
71. A National and State Profile of Leading Health Problems and Health Care Quality for US Children: Key Insurance Disparities and Across-State Variations Bethell, C 2011
https://www.academicpedsjnl.net/article/S1876-2859(10)00250-0/fulltext
72. Dynamics of obesity and chronic health conditions among children and youth cleave 2010.
https://pubmed.ncbi.nlm.nih.gov/20159870/
73. Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders Hooker, B. et al.2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268563/
74. Health effects in vaccinated versus unvaccinated children, with covariates for breastfeeding status and type of birth HookerB. et al. 2021
https://www.oatext.com/pdf/JTS-7-459.pdf
75. Lyons Weiler Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination Lyons-Weiler J. et al. 2020
https://pubmed.ncbi.nlm.nih.gov/33266457/
76. Retraction: Lyons-Weiler, J.; Thomas, P. Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination. Int. J. Environ. Res. Public Health 2020, 17, 8674
https://pubmed.ncbi.nlm.nih.gov/34360528/
77. Correction: Lyons-Weiler, J., et al. Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses along the Axis of Vaccination. Int. J. Environ. Res. Public Health 2020, 17, 8674 James Lyons-Weiler 1 , Paul Thomas
https://pubmed.ncbi.nlm.nih.gov/33499430/
78. Revisiting Excess Diagnoses of Illnesses and Conditions in Children Whose Parents Provided Informed Permission to Vaccinate Them James Lyons-Weiler ET AL.2022
https://www.researchgate.net/publication/363882194_Revisiting_Excess_Diagnoses_of_Illnesses_and_Conditions_in_Children_Whose_Parents_Provided_Informed_Permission_to_Vaccinate_Them
79. Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12-year-old U.S. children Mawson A. et al. 2017
https://www.oatext.com/pdf/JTS-3-186.pdf
80. Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12-year-old U.S. children Anthony R Mawson 2017
https://www.oatext.com/pdf/JTS-3-187.pdf
81. The relationship between vaccination and self report of atopic disease in children Enriquez R. Et al. 2005
https://pubmed.ncbi.nlm.nih.gov/15805992/
82. Vax-Unvax: Let the Science Speak (Children’s Health Defense)
https://mitpressbookstore.mit.edu/book/9781510766969
83. Lotter V. Epidemiology of autistic conditions in young children 1966
https://link.springer.com/article/10.1007/BF00584048
84. https://www.cdc.gov/ncbddd/autism/data.html
85. Autism and Deveopmental Disabilities Monitoring Network 2023
https://www.cdc.gov/ncbddd/autism/pdf/ADDM-Community-Report-SY2020-h.pdf
86. Prevalence of Autism (including Asperger Syndrome) in School Age Children in Northern Ireland Annual Report 2023
https://www.health-ni.gov.uk/sites/default/files/publications/health/asd-children-ni-2023.pdf
87. The proportion of minimally verbal children with autism spectrum disorder in a community-based early intervention programme. Rose V. 2016
https://pubmed.ncbi.nlm.nih.gov/27120989/
88. National Autistic Society New shocking data highlights the autism employment gap
https://www.autism.org.uk/what-we-do/news/new-data-on-the-autism-employment-gap
89. emergence of asd in simplex families: relations to parental perceptions on etiology
Goin Kochel R. 2015
https://pubmed.ncbi.nlm.nih.gov/25398603/
90. parental perceptions and use of complementary and alternative medicine practices for children with asd in private practice harrington J. 2006
https://pubmed.ncbi.nlm.nih.gov/16685182/
91. https://www.cdc.gov/vaccinesafety/concerns/autism.html
92. Adverse Effects of Vaccines Evidence and Causlity
https://nap.nationalacademies.org/catalog/13164/adverse-effects-of-vaccines-evidence-and-causality
93. Does Vaccination Increase the Risk of Autism Spectrum Disorder? Mohammed et al. 2022.
https://pubmed.ncbi.nlm.nih.gov/36110492/
94. Vaccine Safety: Myths and Misinformation Geoghegan et al. 2020.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090020/
95. The myth of vaccination and autism spectrum Gabis et al. 2021.
https://pubmed.ncbi.nlm.nih.gov/34996019/
96. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies Taylor L. et al. 2014
https://pubmed.ncbi.nlm.nih.gov/24814559/
97. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults Fraiman J. et al. 2022
https://pubmed.ncbi.nlm.nih.gov/36055877/
98. FDA oversight of clinical trials is “grossly inadequate,” say experts.
https://www.bmj.com/content/379/bmj.o2628
99. React 19 group
https://react19.org/science
100. Excess deaths in 2023 Campbell, J.
https://www.youtube.com/watch?v=nJ0QL7EwJp4
101. https://www.militaryaccountability.com/
102. Industry reduced early-stage research, favoring medical devices, bioengineered drugs, and late-stage clinical trials Moses, H. 2015
https://pubmed.ncbi.nlm.nih.gov/25585329/
103. Trial sans Error: How Pharma-Funded Research Cherry-Picks Positive Results
https://www.scientificamerican.com/article/trial-sans-error-how-pharma-funded-research-cherry-picks-positive-results/
104. The Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies Gazendam,1. et al. 2022
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951352/
105. How pharmaceutical industry funding affects trial outcomes: Causal structures and responses? Author links open overlay panel Sergio Sismondo 2008
https://www.sciencedirect.com/science/article/abs/pii/S0277953608000361
106. Cochrane Industry sponsorship and research outcome
https://www.cochrane.org/MR000033/METHOD_industry-sponsorship-and-research-outcome
107. Industry Funding of Clinical Trials: Benefit or Bias? Sameer S. Chopra, AM
https://jamanetwork.com/journals/jama/fullarticle/196846
108. Evidence-based medicine has been hijacked: a report to David Sackett 2003
https://www.jclinepi.com/article/S0895-4356%2816%2900147-5/abstract?cc=y=
://fas.org/sgp/crs/misc/R43341.pdf
109. Scientific American: How drug company money is undermining science.
https://www.scientificamerican.com/article/how-drug-company-money-undermining-science/
110. Epistemic Corruption, the Pharmaceutical Industry, and the Body of Medical Science Sismondo, S. 2021
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028448/
111. Cochrane Industry sponsorship and research outcome
https://pubmed.ncbi.nlm.nih.gov/23235689/
112. The decline of science at the FDA has become unmanageable Ross B 2023
https://www.bmj.com/content/381/bmj.p1061
113. https://vaxxedthemovie.com/stream/
114. https://www.merck.com/news/dr-julie-l-gerberding-to-retire-from-merck/
115. https://www.merck.com/news/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health/
116. Improving medical research in the United Kingdom Stephen H. Bradley, Nicholas J. DeVito, Kelly E. Lloyd, Patricia Logullo & Jessica E. Butler 2022
https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-022-06050-y
117. https://www.britannica.com/biography/Ignaz-Semmelweis
118. Suppressing Scientific Discourse on Vaccines? Self-perceptions of researchers and practitioners Elisha E 2022
https://pubmed.ncbi.nlm.nih.gov/35587319/
119. Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile
120. Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/a11282023cyfendus.htm
121. Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
122. Statistica
https://www.statista.com/topics/1719/pharmaceutical-industry/#topicOverview
123. Possible role of L-form switching in recurrent urinary tract infection. Mickiewicz et al. 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763468/
124. Repurposing Drugs with Specific Activity Against L-Form Bacteria. Emami et al. 2023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110866/pdf/fmicb-14-1097413.pdf
125. Trends in Allergic Conditions Among Children: United States, 1997–2011. Jackson et al. 2013.
https://www.cdc.gov/nchs/products/databriefs/db121.htm
126. Unyielding: Marathons Against Illegal Mandates. Thomas L. Rempfer, Philip G. Zimbardo. 2024. ISBN: 9781648210457
https://www.skyhorsepublishing.com/9781648210457/unyielding/
126 Appendix P. Memorandum from Contracting Officer at Fort Detrick. 3rd May 1999.
126 Appendix Q. Emails from Brigadier Eddie Cain. 3rd May 1999.
126 Appendix R. Memorandum: Reaffirmation of Military Requirement for Anthrax Vaccine Program. 18th August 2001.
126 Appendix S. Memorandum: Strategy Development for Force Health Protection Against Biological Threats. August 10th 2001.
126 Appendix U. Memorandum: Minutes of on Changing the Food and Drug Administration License for the Michigan Department of Public Health (MDPH) Anthrax Vaccine to Meet Military Requirement. 13th November 1995.
126 Appendix V. Food and Drug Administration Investigational New Drug Applications by MBPI and BioPort. 20th September 1996 and 1999.
127. DoD Directive: DoD Immunization Program for Biological Warfare Defense November 26th 1993.
https://apps.dtic.mil/sti/tr/pdf/ADA275188.pdf
128. Biological Threats and Terrorism: Assessing The Science and Response Capabilities: Workshop Summary: Vaccines: Research, Development, Production, and Procurement Issues 2002.
https://www.ncbi.nlm.nih.gov/books/NBK98400/
129. Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military: Resources, Responsibilities, and Dynamics in the Military's Vaccine Mission.
https://www.ncbi.nlm.nih.gov/books/NBK220960/
130. Is Military Research Hazardous to Veteran’s Health? Lesson Spanning Half a Century. December 8th 1994.
https://apps.dtic.mil/sti/pdfs/ADA291587.pdf
131. United States General Accounting Office: Safety and Efficacy of the Anthrax Vaccine. Statement of Kwai-Cheung Chan, Director, Special Studies and Evaluations, National Security and International Affairs Division April 29th, 1999.
https://www.gao.gov/assets/t-nsiad-99-148.pdf
132. Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors.
https://www.emergentbiosolutions.com/press/news-release-details-dr-kathryn-c-zoon-appointed-emergent-biosolutions-board/
133. Office of the Assistant Secretary of Defense (Public Affairs) Background Briefing. August 5th, 1999.
https://www.globalsecurity.org/space/library/news/1999/x08051999_x0805ant.htm
134. Canadian soldier wins anthrax case. May 5th, 2000.
https://www.upi.com/Archives/2000/05/05/Canadian-soldier-wins-anthrax-case/7921957499200/
135. H.R.2548 - To suspend further implementation of the Department of Defense anthrax vaccination program until the vaccine is determined to be safe and effective and to provide for a study by the National Institutes of Health of that vaccine. 106th Congress (1999-2000) Introduced 07/19/1999.
https://www.congress.gov/bill/106th-congress/house-bill/2548
136. Persian Gulf War Illnesses: Are We Treating Veterans Right? November 16th 1993.
https://ia801306.us.archive.org/26/items/persiangulfwaril00unit/persiangulfwaril00unit.pdf
137. U.S. ex rel. Dingle v. Bioport Corp Decision. 18th June 2003.
https://case-law.vlex.com/vid/u-s-ex-rel-892615320
138. United States General Accounting Office: Anthrax Vaccine, Changes to the Manufacturing Process. Statement of Nancy Kingsbury, Ph.D., Managing Director, Applied Research and Methods.
https://www.gao.gov/assets/gao-02-181t.pdf
139. September 11, 2001 : Attack on America. DoD News Briefing - Secretary Rumsfeld and Gen. Myers. October 18th, 2001.
https://avalon.law.yale.edu/sept11/dod_brief44.asp
140. Research Advisory Committee on Gulf War Veterans Illnesses Lesson Learned 12/16/2002.
https://www.va.gov/RAC-GWVI/docs/Committee_Documents/Letter_LessonsLearned_Dec2002.pdf
141. Anthrax Vaccine Adsorbed Package Inserts Revision: January 31, 2002.
https://www.ncbi.nlm.nih.gov/books/NBK220516/
142. Scientists Advise on Anthrax Vaccine Dec 20, 2001.
https://www.mrt.com/news/article/Scientists-Advise-on-Anthrax-Vaccine-7847651.php
143. CNN: Postal, Capitol Hill workers offered vaccine. December 20th, 2001.
https://www.cnn.com/2001/US/12/18/anthrax/
144. Department of Health and Human Services: Re: Docket No. OlP-0471/CPl 0J27J2002.
https://img1.wsimg.com/blobby/go/4fa7f468-a250-4088-926e-3c56a998df1f/downloads/FDA%20response%20to%20Citizen%20Petition_80027a9f.pdf?ver=1620969217312
145. §1107. Notice of use of an investigational new drug or a drug unapproved for its applied use.
https://www.govinfo.gov/content/pkg/USCODE-2020-title10/html/USCODE-2020-title10-subtitleA-partII-chap55-sec1107.htm
146. Senate Resolution 278: Expressing the Sense of the Senate Regarding the Anthrax and Small Pox Vaccines.
https://www.govinfo.gov/content/pkg/CREC-2003-11-25/html/CREC-2003-11-25-pt1-PgS16031-4.htm
147. Institute for Defense Analyses: Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements.
https://apps.dtic.mil/sti/tr/pdf/ADA388211.pdf
148. Authorization of Emergency Use of Anthrax Vaccine Adsorbed for Prevention of Inhalation Anthrax by Individuals at Heightened Risk of Exposure Due to Attack With Anthrax; Availability A Notice by the Food and Drug Administration on 02/02/2005.
https://www.federalregister.gov/documents/2005/02/02/05-2028/authorization-of-emergency-use-of-anthrax-vaccine-adsorbed-for-prevention-of-inhalation-anthrax-by
149. The United States Department of Justice: Amerithrax Investigative Summary. February 19th , 2010.
https://www.justice.gov/archive/amerithrax/docs/amx-investigative-summary.pdf
150. Salon: The anthrax vaccine scandal.
https://www.salon.com/2001/10/15/anthrax_vaccine/
151. Transcript: Defense Department Briefing, October 12th, 2001.
https://www.globalsecurity.org/military//library/news/2001/10/mil-011012-usia05b.htm
152. Citizen’s Petition by Russel Dingle and Thomas Rempfer
https://img1.wsimg.com/blobby/go/4fa7f468-a250-4088-926e-3c56a998df1f/downloads/citizen%20petition%20ava%20rempfer%20dingle.pdf?ver=1620969217312
153. Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid
Anthony R. Mawson et L. 2025
154. GAO: Anthrax Vaccine Safety and Efficacy Issues. Statement of Kwai-Cheung Chan, Director, Special Studies and Evaluations, National Security and International Affairs Division.
https://www.gao.gov/assets/t-nsiad-00-48.pdf
155. Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid. Anthony R. Mawson1, Binu Jacob1.
https://ijvtpr.com/index.php/IJVTPR/article/view/100
156. Anthrax Vaccines in the 21st Century. Apostolos P Georgopoulos et al. 2024.
157. Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural Infection. Ascough et al. 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9610610/
158. Cellular immune activation in Gulf War veterans. Skowera et al. 2004.
https://pubmed.ncbi.nlm.nih.gov/14997036/
159. Impaired immune function in Gulf War Illness. Whistler et al. 2009.
https://pubmed.ncbi.nlm.nih.gov/19265525/
160. Blood Biomarkers of Chronic Inflammation in Gulf War Illness. Johnson et al. 2016.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4924830/
161. Gulf War Illness and Inflammation: Association of symptom severity with C-reactive protein. James et al. 2019.
https://www.jneurology.com/articles/gulf-war-illness-and-inflammation-association-of-symptom-severity-with-creactive-protein.html
162. Ocular and inflammatory markers associated with Gulf War illness symptoms. Kalahasty et al. 2023.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9981620/
163. Gulf War illness (GWI) as a neuroimmune disease. Georgopoulos et al. 2017.
https://pubmed.ncbi.nlm.nih.gov/28762055/
164. Lupus Anticoagulant in Gulf War Illness and Autoimmune Disorders: A Common Pathway Toward Autoimmunity. James et al. 2021.
https://www.immunologyresearchjournal.com/articles/lupus-anticoagulant-in-gulf-war-illness-and-autoimmune-disorders-a-common-pathway-toward-autoimmunity.html
165. Iraq and Afghanistan Veterans report symptoms consistent with chronic multisymptom illness one year after deployment. McAndrew et al. 2016.
https://pubmed.ncbi.nlm.nih.gov/27006173/
166. Reduced Human Leukocyte Antigen (HLA) Protection in Gulf War Illness (GWI). Georgopoulos et al. 2015.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4739436/
167. Human Leukocyte Antigen (HLA) and Gulf War Illness (GWI): HLA-DRB1*13:02 Spares Subcortical Atrophy in Gulf War Veterans. James et al. 2017.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5832612/
168. Human Leukocyte Antigen (HLA) Alleles Prevent Metabolically-Induced Inflammation and Cerebrocortical Thinning in Gulf War Illness. Christover et al. 2020.
https://www.jneurology.com/articles/human-leukocyte-antigen-hla-alleles-prevent-metabolically-induced-inflammation-and-cerebrocortical-thinning-in-gulf-war-illness.html
169. Adverse effects of Gulf War Illness (GWI) serum on neural cultures and their prevention by healthy serum. Georgopoulos et al. 2018.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6486178/
170. Anthrax and Gulf War Illness (GWI): Evidence for the Presence of Harmful Anthrax Antigen PA63 In the Serum of Veterans with GWI. Tsilibary et al. 2019.
https://www.jneurology.com/articles/anthrax-and-gulf-war-illness-gwi-evidence-for-the-presence-of-harmful-anthrax-antigen-pa63-in-the-serum-of-veterans-with-gwi.html
171. Subcortical brain atrophy in Gulf War Illness. Christova et al. 2017.
https://pubmed.ncbi.nlm.nih.gov/28634886/
172. Anthrax Protective Antigen 63 (PA63): Toxic Effects in Neural Cultures and Role in Gulf War Illness (GWI). Tsilibary et al. 2017.
https://pubmed.ncbi.nlm.nih.gov/32656531/
173. Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined
Committee on the Development of a Consensus Case Definition for Chronic Multisymptom Illness in 1990-1991 Gulf War Veterans; Board on the Health of Select Populations; Institute of Medicine
https://pubmed.ncbi.nlm.nih.gov/25590117/
174. The Anthrax Vaccine Program: An Analysis of the CDC's Recommendations for Vaccine Use. Meryl Nass 1 2002.
https://pmc.ncbi.nlm.nih.gov/articles/PMC1447151/
175
Gold hamsters vaccinated with 221 strains showed, absence of protection. STI-1 immunisation protected against the H-7 strain, but did not protect against the recombinant strain
https://pubmed.ncbi.nlm.nih.gov/25032373/
176. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. A P Pomerantsev. 1997
https://pubmed.ncbi.nlm.nih.gov/9413092/
177. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. K Fukuda 1998.
https://pubmed.ncbi.nlm.nih.gov/9749480/